On August 4 2023, OWENS & MINOR ($NYSE:OMI) reported their second quarter of the fiscal year 2023 earnings results, showing that total revenue for the quarter had increased by 2.5% from the same period the previous year, amounting to USD 2563.2 million. Unfortunately, net income was down from USD 28.6 million in the previous year to USD -28.2 million for this quarter.
The company’s stock opened at $18.2 and closed at $19.0, up 1.3% from its prior closing price of 18.8. The company attributed the decrease in operating profit to higher restructuring charges and lower sales volume. Overall, OWENS & MINOR had a solid second quarter financial performance and is continuing to grow and expand its operations. Investors should keep a close eye on the company’s progress over the coming quarters to ensure that it is able to maintain its growth momentum and stay ahead of its competition. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for OMI. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for OMI. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for OMI. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for OMI are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – OMI Intrinsic Value
GoodWhale has conducted an analysis of OWENS & MINOR’s financials, and by our proprietary Valuation Line, we have determined that its intrinsic value is around $30.9. Currently, OWENS & MINOR stock is trading at $19.0, meaning the stock is undervalued by 38.5% according to our analysis. We recommend that investors take advantage of this opportunity and buy the stock while the price is currently lower than its intrinsic value. More…
Risk Rating Analysis
Star Chart Analysis
Owens & Minor Inc is in the business of distributing medical supplies and providing related services to healthcare providers. The company operates in North America and Europe. Its competitors include Orthofix Medical Inc, Medirect Latino Inc, PT Millennium Pharmacon International Tbk.
– Orthofix Medical Inc ($NASDAQ:OFIX)
Orthofix Medical Inc is a medical device company that provides orthopedic solutions to patients worldwide. The company has a market cap of 297.51M as of 2022 and a Return on Equity of -4.8%. The company’s products are used in the treatment of various conditions, including osteoarthritis, degenerative disc disease, scoliosis, and deformities. The company’s products are sold through a network of distributors and retailers.
– Medirect Latino Inc ($OTCPK:MLTO)
PT Millennium Pharmacon International Tbk is a leading pharmaceutical company in Indonesia with a market cap of 156.7B as of 2022. The company has a strong focus on research and development, and has a strong portfolio of products. The company has a Return on Equity of 17.77%.
OWENS & MINOR reported total revenue of USD 2563.2 million for the second quarter of its fiscal year 2023, ending June 30 2023. This figure represents a 2.5% increase year-over-year. Unfortunately, their net income of USD -28.2 million is a decrease from last year’s figure of USD 28.6 million. Investors should take these results into consideration when assessing any potential investments in OWENS & MINOR.
It is important to note that although revenue has increased, net income has decreased and this could be an indicator of potential financial difficulties or investments that have yet to pay off. It is worth monitoring the company’s performance to see if they can turn things around in the coming quarters.